Moreau v. United States Olympic & Paralympic Committee

Filing 307

ORDER denying 170 United States Olympic & Paralympic Committe's Motion to Dismiss; denying 173 Plaintiff's Special Motion to Dismiss Defendant United States Olympic & Paralympic Committee's Counterclaims by Judge Charlotte N. Sweeney on 11/18/22.(jdyne)

IN THE UNITED STATES DISTRICT COURT
FOR THE DISTRICT OF COLORADO
Judge Charlotte N. Sweeney
Civil Action No. 1:20-cv-00350-CNS-MEH
DR. WILLIAM MOREAU,
Plaintiff,
v.
UNITED STATES OLYMPIC & PARALYMPIC COMMITTEE,
Defendant.

ORDER

Before the Court is Plaintiff Dr. William Moreau’s Special Motion to Dismiss Defendant
United States Olympic & Paralympic Committee’s (“USOPC’s”) Counterclaims Pursuant to
C.R.S. § 13-20-1101 (ECF No. 171), and USOPC’s Motion to Dismiss Dr. Moreau’s First
Amended Complaint (ECF No. 170). For the following reasons, the Court DENIES both motions.
I. BACKGROUND FOR DR. MOREAU’S MOTION TO DISMISS 1
USOPC serves as both the National Olympic Committee and National Paralympic
Committee for the United States (ECF No. 66 at 44-45 ¶ 5). Dr. Moreau worked for USOPC from
May 2009 through May 2019 (Id. at 45 ¶ 6). From December 2009 through May 2019, Dr. Moreau
led USOPC’s Sports Medicine Department and was responsible for “building an integrated multidisciplinary approach to healthcare” for U.S. athletes (Id. at 45 ¶ 7). Dr. Moreau was the Vice

The background facts are taken from the well-pleaded allegations in USOPC’s Counterclaims, drawn from its First
Amended Answer to Complaint and Counterclaims, and interpreted in light most favorable to USOPC (See ECF No.
66). See also Porter v. Ford Motor Co., 917 F.3d 1246, 1248 n.1 (10th Cir. 2019); Mayfield v. Bethards, 826 F.3d
1252, 1255 (10th Cir. 2016).
1

1

President of Sports Medicine from 2019 through May 2019 (Id. at 46 ¶ 9). During his tenure at
USOPC, Dr. Moreau had access to “confidential and proprietary” information belonging to
USOPC (Id. at 45 ¶ 8). This information concerned USOPC’s policies, contractual terms of service
for U.S. athletes, information regarding the athletes themselves, “HR and personnel matters,” and
“legal actions” (Id. at 45-46, 56-57 ¶¶ 8, 72-73).
As a USOPC employee, Dr. Moreau was given a work email account (Id. at 46 ¶ 12). He
acknowledged throughout his employment that he was bound by the terms of USOPC’s Employee
Handbook, its Code of Conduct and its “Confidentiality & No Prohibited Contact Statement” (Id.
at 46, 48 ¶¶ 13-14, 25). At the time he was hired, USOPC also provided Dr. Moreau with its
“Property Issue/Return Policy,” which stated that when his employment ended, he was required to
return all USOPC property to USOPC (Id. at 48 ¶ 23). USOPC also implemented a “Document
Management Policy” that required employees to maintain any company emails and documents in
a policy-approved storage location (See id. at 51 ¶ 44). Dr. Moreau was told several times during
his employment that he was prohibited from disclosing confidential information to “unauthorized
persons,” and that he was bound by this requirement even after his employment with USOPC
ended (See, e.g., id. at 66 ¶¶ 52-55).
During his employment, Dr. Moreau sent or forwarded emails from his USOPC email
account to an email account associated with his “side business,” DCOnline (Id. at 56 ¶ 70). He
also printed confidential emails and documents (Id. at 56 ¶ 71). Some of these documents and
emails contained alleged USOPC “trade secrets” (See id. at 57 ¶ 73). When Dr. Moreau’s
employment ended in May 2019, he did not return any of the printed documents or emails
forwarded to his DCOnline account, and still has some of these documents in his possession (See
id. at 58 ¶¶ 77, 79). Dr. Moreau deleted or destroyed other emails and documents (Id. at 58 ¶ 80).

2

After taking these emails and documents, Dr. Moreau shared them with “third parties” (Id.
at 59 ¶ 86). In February 2020, Dr. Moreau sued USOPC, and included “extensive confidential and
proprietary information” belonging to USOPC in his initial complaint (Id. at 59 ¶ 88). Dr. Moreau
provided USOPC with his Initial Disclosures in April 2020, at which time USOPC learned Dr.
Moreau had taken documents from USOPC (Id. at 59-60 ¶ 89). In May 2020, USOPC received
written discovery responses from Dr. Moreau which contained allegedly confidential and
proprietary information (Id. at 60 ¶ 90). Dr. Moreau “admitted to taking USOPC property” and
“not returning such property upon his termination” in his June 2020 deposition (Id. at 60 ¶ 92).
USOPC filed its Counterclaims in September 2020, bringing claims for civil theft, conversion,
breach of contract, and violations of the Defend Trade Secrets Act and Colorado Uniform Trade
Secrets Act based on Dr. Moreau’s alleged taking of USOCP’s confidential and proprietary
information (See ECF No. 66).
II. ANALYSIS OF DR. MOREAU’S MOTION
Having considered USOPC’s Counterclaims, Dr. Moreau’s Motion, USOPC’s Response,
Dr. Moreau’s Reply, the briefs’ attachments, and relevant legal authority, the Court denies Dr.
Moreau’s Motion. The Court addresses Dr. Moreau’s arguments in turn.
A. Application of Colorado’s anti-SLAPP Law in Federal Court
Dr. Moreau argues that C.R.S. § 13-20-1101, Colorado’s anti-SLAPP 2 statute, applies in
federal court—and therefore to USOPC’s Counterclaims—because its enforcement in federal
court guards a “substantive right” that does not run afoul of the Federal Rules Enabling Act, 28
U.S.C. § 2072, or Shady Grove Orthopedic Associates, P.C. v. Allstate Insurance Company, 559

2

“SLAPP” stands for “Strategic Lawsuits Against Public Participation.”

3

U.S. 393 (2010) (ECF No. 171 at 12). 3 USOPC contends that Colorado’s anti-SLAPP law is a
“procedural tool” inapplicable in federal court (ECF No. 209 at 2, 10). According to USOPC, the
Federal Rules of Civil Procedure are the “sole available methods” for the relief that Dr. Moreau
seeks, and that because the anti-SLAPP law is a state rule of procedure, it “conflicts” with them
and cannot be applied in federal court (Id. at 3, 13). The Court agrees with Dr. Moreau that
Colorado’s anti-SLAPP statute is applicable in federal court.
As a threshold matter, the Court notes that few state appellate courts and federal district
courts have addressed the scope of Colorado’s anti-SLAPP statute. See, e.g., L.S.S. v. S.A.P., 2022
COA 123, ¶ 20 (Colo. App. 2022) (“[F]ew cases have applied Colorado’s anti-SLAPP statute.”);
Stevens v. Mulay, No. 19-CV-01675-REB-KLM, 2021 WL 1153059, at *2 n.7 (D. Colo. Mar. 26,
2021) (“Colorado’s anti-SLAPP law is relatively new and untested.”). Because Colorado’s antiSLAPP statute “tracks California’s [anti-SLAPP] statute almost exactly,” state and federal courts
have turned to California courts’ interpretation of California’s anti-SLAPP statute in construing
and applying Colorado’s anti-SLAPP statute. See Stevens, 2021 WL 1153059, at *2 n.7; see also
L.S.S., 2022 COA 123, ¶ 20 (“[W]e look to California case law for guidance” in “considering a
special motion to dismiss” under Colorado’s anti-SLAPP law”); cf. Cal. Civ. Proc. Code § 425.16.
The Court likewise turns to other courts’ construction of § 425.16 in analyzing Colorado’s antiSLAPP law.
Dr. Moreau contends application of Colorado’s anti-SLAPP law in federal court is proper
under Justice Stevens’ concurrence Shady Grove, 559 U.S. 393 (2010) (See ECF No. 171 at 9-

The Court has jurisdiction over this action and USOPC’s Counterclaims pursuant to 36 U.S.C. § 220505(b)(9).
Under § 220505(b)(9), when a plaintiff sues a federally charted corporation such as USOPC and the suit relates to
“the corporation’s responsibilities,” the corporation may remove the action to federal district court. The district court
shall have original jurisdiction “without regard to the amount in controversy or citizenship of the parties involved.”
Id. The Court has supplemental jurisdiction over USOPC’s state and common law counterclaims under 28 U.S.C. §
1367.

3

4

12). 4 The Court acknowledges that federal appellate courts are split on the applicability of certain
states’ anti-SLAPP laws in federal court under Shady Grove. See Abbas v. Foreign Pol’y Grp.,
LLC, 783 F.3d 1328, 1337 (D.C. Cir. 2015) (“A federal court exercising diversity jurisdiction
therefore must apply Federal Rules 12 and 56 instead of the D.C. Anti–SLAPP Act’s special
motion to dismiss provision.”); but see Godin v. Schencks, 629 F.3d 79, 86 (1st Cir. 2010)
(“[N]either [Rules 12 or 56 were] meant to control the particular issues under” Maine’s antiSLAPP statute). The Tenth Circuit has also concluded that New Mexico’s anti-SLAPP statute is a
purely “procedural mechanism” inapplicable in federal court. Los Lobos Renewable Power, 885
F.3d at 673. 5 But—as the parties and Colorado courts acknowledge—cases interpreting
California’s anti-SLAPP law guide the Court’s analysis, as the California anti-SLAPP statute is
most similar to Colorado’s anti-SLAPP statute (ECF Nos. 171 at 12, 209 at 12). See also L.S.S.,
2022 COA 123, ¶ 20; Stevens, 2021 WL 1153059, at *2 n.7.

Under the framework set forth in Justice Stevens’ Shady Grove concurrence, state laws that solely address procedural
issues do not apply in federal court. See Shady Grove, 559 U.S. at 417 (Stevens, J., concurring). However, Justice
Stevens stated that “federal courts must apply” certain state procedural rules if they function “as part of the State’s
definition of substantive rights and remedies.” Id. at 416–17. Shady Grove concerned the applicability of state law in
federal diversity actions. See id. As noted above, the Court has jurisdiction over this action pursuant to 36 U.S.C. §
220505. Nonetheless, the Court finds that Shady Grove’s emphasis on the applicability of state law in the diversity
context does not limit its relevance here, given especially that Colorado’s anti-SLAPP law is a state law Dr. Moreau
seeks to enforce in federal court. Moreover, the Tenth Circuit has applied Shady Grove in analyzing another antiSLAPP statute’s applicability in federal court. See Los Lobos Renewable Power, LLC v. Americulture, Inc., 885 F.3d
673 (10th Cir. 2018). See also Barnett v. Hall, Estill, Hardwick, Gable, Golden & Nelson, P.C., 956 F.3d 1228, 1237
n.2 (10th Cir. 2020) (concluding that same conflicts analysis applies in diversity actions and to state law claims under
supplemental jurisdiction).
4

USOPC argues Los Lobos is dispositive and precludes the application of Colorado’s anti-SLAPP statute in federal
court (ECF No. 209 at 11). The Court disagrees. Los Lobos and New Mexico’s anti-SLAPP law it analyzed are
meaningfully distinguishable. The Los Lobos court reasoned that New Mexico’s anti-SLAPP law was “purely
procedural . . . .” 885 F.3d at 670 (original emphasis). Indeed, unlike Colorado and California’s anti-SLAPP statutes,
New Mexico’s anti-SLAPP statutes does not impose a burden shifting framework on parties. See N.M.S.A.§ 38-2-9.1;
cf. § 13-20-1101(3)(c); § 425.16(b)(3). The Los Lobos court itself recognized the absence of this burden-shifting
framework in New Mexico’s anti-SLAPP statute was central to its analysis, and distinguished California’s anti-SLAPP
statute on this basis. See 885 F.3d at 670 (“Unlike many other states’ anti-SLAPP statutes that shift substantive burdens
of proof or alter substantive standards, or both, under no circumstance will the New Mexico anti-SLAPP statute have
any bearing on the suit’s merits determination” (citing Makaeff v. Trump Univ., LLC, 715 F.3d 254 (9th Cir. 2013) to
distinguish California anti-SLAPP statute from New Mexico’s statute) (first two emphases added)). For this reason
Los Lobos does not advance USOPC’s argument.
5

5

Federal courts in California, including the Ninth Circuit, have determined that California’s
anti-SLAPP law applies in federal court. See, e.g., Verizon Delaware, Inc. v. Covad Commc’ns
Co., 377 F.3d 1081, 1091 (9th Cir. 2004). The Ninth Circuit had recent occasion to address whether
its “long line of precedents holding that California’s anti-SLAPP statute applies in federal court”
are “irreconcilable” with Shady Grove. CoreCivic, Inc. v. Candide Grp., LLC, 46 F.4th 1136, 1138
(9th Cir. 2022). They are not. See id. at 1143. The Ninth Circuit concluded Shady Grove was
“reconcilable” with its own interpretation of California’s anti-SLAPP statute in prior cases,
including Planned Parenthood Fed’n of Am., Inc. v. Ctr. for Med. Progress, 890 F.3d 828, 833–
34 (9th Cir.), amended, 897 F.3d 1224 (9th Cir. 2018). See id. Shady Grove and California’s antiSLAPP statutes were reconcilable, the Ninth Circuit reasoned, because California’s anti-SLAPP
statute has been interpreted to eliminate conflicts between standards in the Federal Rules of Civil
Procedure and the anti-SLAPP statute. See id. California’s anti-SLAPP statute is applicable in
federal court because, under the Ninth Circuit’s construction of the statute, challenges to the “legal
sufficiency” claims “made pursuant to California’s anti-SLAPP statute must be analyzed” under
Rule 12(b)(6), and “challenges to [the] factual sufficiency” must be analyzed under the “same
standard as Rule 56 . . . .” Id.; see also Planned Parenthood, 890 F.3d at 833-34. Therefore,
“California’s anti-SLAPP statute applied” in federal court. CoreCivic, 46 F.4th at 1143.
The Court finds CoreCivic’s reasoning persuasive. Moreover, prior Ninth Circuit cases—
on which CoreCivic relied in concluding that Shady Grove and California’s anti-SLAPP statute
were reconcilable—that have not explicitly applied the Shady Grove framework have nonetheless
applied the same test used in the Tenth Circuit for assessing potential conflicts between state laws
and federal rules. 6 For example, in Metabolife Int’l, Inc. v. Wornick, 264 F.3d 832, 846 (9th Cir.
When assessing potential conflicts between a state law and federal rule in the Tenth Circuit, a court asks if there is a
“direct collision” between the state law and federal rule; if there is no “direct collision,” then the court must “wade

6

6

2001), the Ninth Circuit concluded two subsections of California’s anti-SLAPP statute
impermissibly “collided” with Rule 56. But see U.S. ex rel. Newsham v. Lockheed Missiles &
Space Co., 190 F.3d 963, 972 (9th Cir. 1999) (concluding California anti-SLAPP statute’s motion
to strike and fee subsections “can exist side by side” with Rules 8, 12, and 56 (quotations omitted)).
In reaching this conclusion, the Metabolife court asked whether use of the anti-SLAPP statute
would result in a “direct collision” with Federal Rule of Civil Procedure 56 and, if not, whether
application of the anti-SLAPP law was appropriate under Erie v. R.R. Co. v. Tompkins, 304 U.S.
64 (1938). 264 F.3d at 845-46 (quotation omitted); see also Newsham, 190 F.3d at 972-93
(analyzing California anti-SLAPP provisions by first asking if “direct collision” with Federal
Rules existed and, if not, that the court must make an “Erie choice” (quotations omitted).
The Ninth Circuit’s analyses of any potential conflicts between California’s anti-SLAPP
statute and the Federal Rules of Civil Procedure are relevant to the Court’s own analysis of
Colorado’s anti-SLAPP statute, given that the Ninth and Tenth Circuit apply the same framework
for assessing potential procedural conflicts between state and federal rules. 7 See Metabolife, 264
F.3d at 845; Racher, 871 F.3d at 1162-63; see also Stevens, 2021 WL 1153059, at *2 n.7 (noting
Colorado’s anti-SLAPP statute “tracks California’s statute almost exactly”). And under this
framework, California’s anti-SLAPP statute has passed muster and applied in federal court. See,
e.g., Metabolife, 264 F.3d at 845-46 (citing Newsham, 190 F.3d at 970-93).
into [the] murky waters” of Erie v. R.R. Co. v. Tompkins, 304 U.S. 64 (1938). See Racher v. Westlake Nursing Home
Ltd. P’ship, 871 F.3d 1152, 1162–63 (10th Cir. 2017) (quotations omitted).
Over the years, the Tenth Circuit has articulated the governing Shady Grove test in different ways. See, e.g.,
Garman v. Campbell Cnty. Sch. Dist. No. 1, 630 F.3d 977, 983 n.7 (10th Cir. 2010); Racher v. Westlake Nursing
Home Ltd. P’ship, 871 F.3d 1152, 1162-64 (10th Cir. 2017) but cf. Stender v. Archstone-Smith Operating Tr., 958
F.3d 938, 943 (10th Cir. 2020). The Court notes the different ways in which the Tenth Circuit has articulated the
Shady Grove test, but follows the Racher formulation of the Shady Grove framework in its analysis because Racher
predates Stender. See Haynes v. Williams, 88 F.3d 898, 900 n.4 (10th Cir. 1996) (instructing courts to follow prior
published Tenth Circuit panel decisions over subsequent panel decisions absent en banc reconsideration or contrary
Supreme Court caselaw).
7

7

Of course, readings of CoreCivic, Planned Parenthood, and Metabolife make clear that not
all provisions of California’s anti-SLAPP law are applicable in federal court. For instance, the
filing of a motion under California’s anti-SLAPP statute stays discovery in an action pending
courts’ resolution of the motion. See § 425.16(g). Colorado’s anti-SLAPP law contains a materially
identical provision. See C.R.S. § 13-20-1101(6) (“All discovery proceedings in the action are
stayed upon the filing of a notice of motion made pursuant to this section.”). 8 The Ninth Circuit
and other California federal courts have held that this provision in California’s anti-SLAPP statute
would conflict with the Federal Rules of Civil Procedure, and for this reason have declined to
enforce this provision as a categorical and immediate discovery stay when adjudicating antiSLAPP motions in federal court. See Metabolife, 264 F.3d at 846 (“[B]ecause the discoverylimiting aspects of [§ 425.16(g)] collide with the discovery-allowing aspects of Rule 56, these
aspects of [the statute] cannot apply in federal court.” (quotation omitted)); see also Todd v.
Lovecruft, No. 19-CV-01751-DMR, 2020 WL 60199, at *8 (N.D. Cal. Jan. 6, 2020) (explaining
application of § 425.16 in federal district court in light of Ninth Circuit law). But—despite the fact
that certain subsections of California’s anti-SLAPP law are applied differently in California federal
courts than California state courts to avoid conflicts with the Federal Rules of Civil Procedure—
nothing prohibits a party from filing a motion under California’s anti-SLAPP statute. See
Metabolife, 264 F.3d at 845–46 (citing Newsham, 190 F.3d at 970–73).
USOPC contends that Colorado’s anti-SLAPP law is inapplicable in federal court because
it, like the anti-SLAPP statute analyzed in Abbas, requires a plaintiff to establish a “reasonable
In its Opposition to Dr. Moreau’s Motion, USOPC contends another provision in Colorado’s anti-SLAPP statute
renders Dr. Moreau’s motion untimely (ECF No. 209 at 1 n.1). This provision in Colorado’s anti-SLAPP statute
requires that anti-SLAPP motions be filed “within sixty-three days after service” of the complaint or counterclaim.
See § 13-20-1101(6). But this time limitation is precisely the type of procedural limitation that the Ninth Circuit has
ruled directly conflicts with the Federal Rules of Civil Procedure and is therefore inapplicable in federal court. Cf.
Metabolife, 264 F.3d at 846. The Court finds the Ninth Circuit’s reasoning persuasive, and declines to bar Dr.
Moreau’s motion on timeliness grounds.
8

8

likelihood that [he] will prevail on [his] claim” under a burden-shifting framework. § 13-201101(3)(c); see also Abbas, 783 F.3d at 1332. Dr. Moreau cites Barnett v. Hall, Estill, Hardwick,
Gable, Golden & Nelson, P.C., 956 F.3d 1228, 1237 (10th Cir. 2020) for the proposition that
federal appellate courts are split on whether anti-SLAPP laws are applicable in federal court (ECF
No. 171 at 9). In Barnett, the Tenth Circuit considered Abbas’s reasoning “persuasive” in assessing
the applicability of Oklahoma’s anti-SLAPP statute, the Oklahoma Citizens Participation Act
(“OCPA”), which contained a similar burden-shifting framework. However, Barnett did not reach
the ultimate question of whether the OCPA was applicable in federal court. See id. at 1238
(declining to “decide that issue” because dismissal of state law claims under district court’s
supplemental jurisdiction was appropriate on other grounds). At most, the Barnett court looked
favorably at Abbas’s conclusion that Washington D.C.’s anti-SLAPP statute—which also
contained a burden-shifting framework—was inapplicable in federal court, while also noting a
circuit split on this issue. See id. at 1237 n.5; id. at 1238. See also Abbas, 783 F.3d at 1333-34.
A district court in the Tenth Circuit, in determining whether Kansas’ anti-SLAPP statute
applied in federal court, also considered Abbas’s persuasiveness. See Caranchini v. Peck, 355 F.
Supp. 3d 1052, 1057 (D. Kan. 2018). Caranchini concluded that Kansas’ anti-SLAPP statute
applied in federal court and rejected Abbas in arriving at this conclusion. Id. at 1061. Abbas did
not control, the Caranchini court reasoned, because Abbas “did not discuss the practical effects of
not applying these statutes in federal court.” Id. (emphasis added). According to Caranchini,
application of Kansas’ anti-SLAPP law was “most consistent with the purposes of the Erie
doctrine”: the statute’s federal court application discouraged forum shopping and “inequitable
administration of the laws.” Id. at 1060 (citation omitted).

9

The First Circuit, in concluding Maine’s anti-SLAPP law—which also contains a burdenshifting framework—was applicable in federal court, likewise considered Erie’s “dual aims” in
arriving at its conclusion. Godin, 629 F.3d at 91-92 (“Declining to apply [Maine’s anti-SLAPP
statute] in federal court would disserve the dual aims of Erie” (capitalization omitted)). 9 Abbas
and Barnett failed to consider Erie at all in reaching their contrary conclusions. But if, as the
Barnett court suggested, there is “no real difference between the OCPSA and the Federal Rules,”
then Tenth Circuit precedent would require consideration of Erie at the next stage of analyzing a
potential conflict between an anti-SLAPP statute and the Federal Rules. See Racher, 871 F.3d at
1163 (“If there is no direct collision, however . . . the [conflicts] analysis must proceed under Erie.”
(citation omitted)).
Like Godin, the Ninth Circuit has interpreted California’s anti-SLAPP statute—which
contains materially identical provisions to Colorado’s anti-SLAPP statute—as existing “side by
side” with Federal Rules of Civil Procedure 8, 12, and 56 without directly colliding. See Newsham,
190 F.3d at 972. According to the Ninth Circuit, these Rules of Civil Procedure were not intended
to “occupy the field” of pretrial procedures aimed at “weeding out” unmeritorious claims.
Newsham, 190 F.3d at 972.; see also Baral v. Schnitt, 1 Cal. 5th 376, 384 (2016) (“[California’s]
anti-SLAPP statute . . . provides a procedure for weeding out, at an early stage, meritless claims
arising from protected activity.”). Moreover, California’s anti-SLAPP statute was “crafted to serve
an interest not directly addressed by the Federal Rules: the protection of ‘the constitutional rights
of freedom of speech and petition for redress of grievances.’” Newsham, 190 F.3d at 972 (quoting
§ 425.16(a)). So too with Colorado’s anti-SLAPP statute. See § 13-20-1101(2)(a)(IV) (protecting

Of course, Godin was not wholly reliant on Erie in determining that Maine’s anti-SLAPP statute applies in federal
court. Godin further concluded that Maine’s anti-SLAPP statue contained “substantive and procedural aspects” and
that the statute did not conflict with Federal Rules 12 and 56. See Godin, 629 F.3d at 89.
9

10

“acts” done “in furtherance of the exercise of the constitutional right of petition” or “right of free
speech”). 10
***
Given that California’s anti-SLAPP statute and Colorado’s anti-SLAPP statute are
“substantively identical,” the Colorado Court of Appeals has directed courts to California law
construing California’s anti-SLAPP statute for construing Colorado’s own anti-SLAPP statute. See
L.S.S., 2022 COA 123, ¶¶ 20, 23. The Ninth Circuit has held that there is no conflict between the
Federal Rules of Civil Procedure and the provisions of California’s anti-SLAPP law that prohibits
the filing of special anti-SLAPP motions. See Metabolife, 264 F.3d at 845–46; see also §
425.16(b). And Colorado’s anti-SLAPP statute contains a substantively identical provision to the
provision in California’s anti-SLAPP statute that the Ninth Circuit has consistently affirmed is
applicable in federal court. See C.R.S. § 13-20-1101(3)(a); see also § 425.16(b); Metabolife, 264
F.3d at 845. Accordingly—in light of the statutes’ substantively identical provisions—the Court
concludes that Colorado’s anti-SLAPP law is applicable in federal court. 11 As CoreCivic

Dr. Moreau notes that there is an “insignificant” difference in California’s and Colorado’s anti-SLAPP statutes
regarding the burden a plaintiff must satisfy (ECF No. 171 at 12). See § 425.16(b)(3) (requiring a plaintiff to show
“probability” of prevailing on claim); but see § 13-20-1101(3)(a) (requiring a plaintiff to show a “reasonable
likelihood” of prevailing on a claim). Despite these textual differences, the Court finds the Ninth Circuit’s reasoning
in Newsham persuasive that Rules 8, 12, 56 do not occupy the field of pretrial procedures, and are not aimed protecting
the rights that the anti-SLAPP statutes are intended to protect. See Newsham, 190 F.3d at 972. Moreover, the Colorado
Court of Appeals has held that the language is California’s anti-SLAPP statute and Colorado’s anti-SLAPP statute are
“substantively the same.” L.S.S., 2022 COA ¶ 23 n.3.
11
As discussed above, the Ninth Circuit has declined to apply the discovery-staying provision of California’s antiSLAPP statute in federal court because this provision does conflict with the Federal Rules. See Metabolife, 264 F.3d
at 846. The parties have not briefed the applicability—or inapplicability—of the discovery-staying provision in
Colorado’s anti-SLAPP law in federal court. For this reason, the Court expresses no opinion on the applicability of
this provision in Colorado’s anti-SLAPP statute; only that, as Dr. Moreau argues, motions under Colorado’s antiSLAPP law are applicable in federal actions (See ECF No. 171 at 9-10).
10

11

explained, nothing in Shady Grove precludes the statute’s application. 12 See CoreCivic, 46 F.4th
at 1143.
B. Application of Colorado’s anti-SLAPP Framework to USOPC’s Counterclaims
Before proceeding in its analysis of Dr. Moreau’s anti-SLAPP motion, the Court provides
a summary of the case’s procedural posture. Discovery closed on October 4, 2022 (See ECF No.
306). Dispositive motions are due by November 28, 2022 (ECF No. 303). Considering this, the
Magistrate Judge recently denied USOPC’s request to dispose Dr. Moreau’s spouse, stating that
discovery “simply has to stop in this case” (ECF No. 306). With this case’s procedural posture in
mind, the Court proceeds in its application of Colorado’s anti-SLAPP statute to USOPC’s
Counterclaims.
In federal cases applying California’s anti-SLAPP statute, courts must determine whether
the basis of an anti-SLAPP motion is legal or factual. See Planned Parenthood, 890 F.3d at 833
(“[Courts] review anti-SLAPP motions . . . under different standards depending on the motion’s
basis”). If the anti-SLAPP motion mounts a legal challenge, courts assess the motion under Federal
Rule of Civil Procedure 12(b)(6). See id. at 833-34. If the anti-SLAPP motion mounts a factual
challenge, courts assess the motion under Federal Rule of Civil Procedure 56. See id. at 834.
Assessment of Dr. Moreau’s legal challenges under Rule 12(b)(6) and his factual challenges under

The Court also notes that Colorado’s anti-SLAPP statute, like New Mexico’s anti-SLAPP statute, imposes an
expedited hearing schedule for anti-SLAPP motions. See § 38-2-9.1(A); see also § 13-20-1101(5). Under Los Lobos,
this provision would likely be inapplicable in federal court. See Los Lobos, 885 F.3d at 669-670. No party has briefed
the applicability of this specific provision in federal court; instead, USOPC argues more broadly that Los Lobos
dispositively precludes application of Colorado’s entire anti-SLAPP statute (See ECF No. 209 at 11). Therefore, the
Court expresses no opinion on the applicability of this provision in Colorado’s anti-SLAPP statute—only that this
specific provision would appear to conflict with the Tenth Circuit’s reasoning in Los Lobos. The Court further notes,
however, that under Ninth Circuit law subsections of California’s anti-SLAPP law that would otherwise violate the
Federal Rules of Civil Procedure or run afoul of Shady Grove have not rendered the entire statute—which, like
Colorado’s, imposes a substantive burden-shifting framework—inapplicable in federal court. See, e.g., Metabolife,
264 F.3d at 846.
12

12

Rule 56 ensures that there is no collision between these Federal Rules and application of
Colorado’s anti-SLAPP statute in federal court. See, e.g., Planned Parenthood, 890 F.3d at 834.
Dr. Moreau appears to mount both legal and factual challenges to USOPC’s Counterclaims,
arguing that the Counterclaims’ allegations “are without factual or legal support” (See ECF No.
171 at 20). Therefore, the Court’s analysis proceeds in two stages. First, the Court applies the antiSLAPP two-step framework to Dr. Moreau’s legal challenge; if any of USOPC’s counterclaims
“[do] not survive that analysis, they [are] dismissed as under Rule 12.” Todd , 2020 WL 60199, at
*8. The Court would then entertain whether to grant leave to amend the Counterclaims. See
Verizon Delaware, Inc. v. Covad Commc’ns Co., 377 F.3d 1081, 1091 (9th Cir. 2004) (“[G]ranting
[an] anti-SLAPP motion to strike . . . without granting . . . leave to amend would directly collide
with Fed. R. Civ. P. 15(a)’s policy favoring liberal amendment.”). Second, after any allowed
amendments to the counterclaims, and after discovery has been conducted, the Court would then
address factual challenges to the subject claims. See Todd, 2020 WL 60199, at *8; accord Planned
Parenthood, 890 F.3d at 834 (concluding that when an anti-SLAPP motion challenges the “factual
sufficiency of a claim,” the Rule 56 standard applies and “discovery must be allowed, with
opportunities to supplement evidence based on the factual challenge before any decision is made
by the court”).
C. Legal Challenge to USOPC’s Counterclaims
With this framework in mind, and having established Colorado’s anti-SLAPP statute
applies, the Court turns to whether USOPC’s Counterclaims survive Dr. Moreau’s motion based
on the legal challenge. This analysis proceeds in two steps. First, the Court must determine whether
the defendant—in this case, Dr. Moreau, as the party defending himself from USOPC’s
Counterclaims —has made a “threshold showing that the conduct” underlying the plaintiff’s claim

13

“falls within the scope of the anti-SLAPP statute.” L.S.S., 2022 COA 123, ¶ 21. This means that
the underlying conduct arises from an act “in furtherance of [the defendant’s] right of petition or
free speech . . . in connection with a public issue.” Id. (citing § 13-20-1101(3)(a)). The burden the
anti-SLAPP statute’s first step imposes is not “particularly demanding.” Todd, 2020 WL 60199,
at *11.
If the defendant—in this instance, Dr. Moreau—meets his step one burden, the Court
proceeds to the anti-SLAPP statute’s second step. There, the Court considers the pleadings and
affidavits and determines whether the plaintiff—in this instance, USOPC—has established a
“reasonable likelihood” of prevailing on his claim. Id. at ¶ 22 (quoting § 13-20-1101(3)(a)-(b)).
This process is identical to the process used in assessing anti-SLAPP motions under California’s
anti-SLAPP statute. See Baral, 1 Cal. 5th at 384 (describing two-step process for resolving antiSLAPP motions). Applying this two-step framework, the Court first considers whether Dr. Moreau
has shown his conduct falls within the anti-SLAPP’s statutes protection, then whether USOPC has
shown it has a reasonable likelihood of prevailing on its counterclaims.
1. Anti-SLAPP Step One
Dr. Moreau argues that he has met his first step burden under Colorado’s anti-SLAPP law
because USOPC’s Counterclaim alleges that he shared USOPC’s proprietary information with
third parties, and that in bringing this lawsuit against USOPC he filed unsealed privileged and
proprietary information (ECF No. 171 at 14-15; see also ECF No. 66 at 59 ¶¶ 86-88). 13 This alleged
conduct, Dr. Moreau contends, amounts to petitioning activity protected under Colorado’s antiSLAPP statute—especially since he retained and used the allegedly proprietary information to

Dr. Moreau also argues that his engagement with the news media is also protected activity under the anti-SLAPP
statute (See ECF No. 171 at 18). The Court need not address this argument because, for the reasons discussed further
below, the allegations in USOPC’s Counterclaims concern Dr. Moreau’s acquisition of its allegedly confidential
material, not his engagement with the news media after filing this lawsuit (See generally ECF No. 66).
13

14

“fram[e] and support” his claims against USOPC (ECF No. 171 at 15). USOPC argues that Dr.
Moreau has not met his first step burden because there is no legal justification for Dr. Moreau’s
conduct, and that its Counterclaims do not “arise” from his right to petition (ECF No. 209 at 1314). Fundamentally, USOPC argues that its Counterclaims “strictly involve” Dr. Moreau’s alleged
misappropriation of its confidential information and trade secrets, not any protected activity under
the anti-SLAPP statute (Id. at 16). The Court agrees with Dr. Moreau.
In determining whether Dr. Moreau has met his first step burden under the anti-SLAPP
statute, the Court examines the “principal thrust or gravamen” of USOPC’s Counterclaims.
Freeman v. Schack, 154 Cal. App. 4th 719, 727 (2007) (quotation and emphasis omitted). Where
a “mixed” claim is based on allegedly protected and unprotected activity under the anti-SLAPP
statute, courts must determine whether the allegedly protected activity is “merely incidental” to
the unprotected conduct. Haight Ashbury Free Clinics, Inc. v. Happening House Ventures, 184
Cal. App. 4th 1539, 1551 (2010) (quotation omitted). When allegations referring to arguably
protected activity are “only incidental to a [claim] based essentially on nonprotected activity,”
these incidental allegations are insufficient to “subject” the claim to the anti-SLAPP statute.
Freeman, 154 Cal. App. 4th at 727 (citation omitted). “This does not suggest, however, that
[courts] need only make a quantitative comparison of allegations of protected versus nonprotected
activity.” Haight Ashbury, 184 Cal. App. 4th at 1552. At step one of the anti-SLAPP inquiry, a
court’s task is “solely to determine whether any portion” of a claim have “even minimal merit
within the meaning of the anti-SLAPP statute.” Oasis W. Realty, LLC v. Goldman, 51 Cal. 4th 811,
825 (2011).
Dr. Moreau identifies several allegations in USOPC’s Counterclaims in support of his
contention that he has met his step one burden; specifically allegations related to his pre-litigation

15

activity (See ECF No. 171 at 15). USOPC alleges that Dr. Moreau disclosed its confidential
information to other individuals “in or around February 2020”—the same month, USOPC alleges,
Dr. Moreau initiated this lawsuit (ECF No. 66 at 59 ¶¶ 87-88). Dr. Moreau disclosed USOPC’s
information by allegedly forwarding information to his own e-mail account, which he then shared
with “a number of third parties” (Id. at 62 ¶ 108). It was after Dr. Moreau initiated this lawsuit that
USOPC learned of his alleged misappropriation of its confidential information (See id. at 60 ¶ 90).
Dr. Moreau’s initial complaint “include[d] extensive confidential and proprietary information”
that USOPC “immediately began investigating” (Id. at 59-60 ¶¶ 88-89). Indeed, the Counterclaim
alleges that Dr. Moreau disclosed his use of USOPC’s confidential information “for the first time”
in April 2020 when providing USOPC with his Initial Disclosures (Id. at 59-60 ¶ 89).
Allegations related to Dr. Moreau’s initiation of this lawsuit are protected by the antiSLAPP statute. To be sure, USOPC’s claim against Dr. Moreau is “mixed”—USOPC’s claim is
based on Dr. Moreau’s alleged retention of its allegedly confidential documents and his decision
to disclose those documents in bringing this lawsuit. Regarding allegations related to this lawsuit,
the constitutional right to petition under the anti-SLAPP statute reaches “communications
preparatory to or in anticipation of” filing a lawsuit. Dove Audio, Inc. v. Rosenfeld, Meyer &
Susman, 47 Cal. App. 4th 777, 784 (1996) (citing § 425.16(e)); cf. C.R.S. § 13-20-1101(2)(a)
(defining protected petitioning and speech activity)). See also Rohde v. Wolf, 154 Cal. App. 4th
28, 35 (2007) (“[S]tatements, writings and pleadings in connection with civil litigation are covered
by the anti-SLAPP statute, and that statute does not require any showing that the litigated matter
concerns a matter of public interest.” (citations omitted). Thus, these allegations are sufficient to
satisfy his step one burden under the anti-SLAPP statute.

16

USOPC argues that despite these allegations, its claim against Dr. Moreau “arises” from
his decision to “disregard clear company policy” and take documents containing confidential
information that “did not belong to him” (ECF No. 209 at 14). In its Counterclaims, USOPC claims
that Dr. Moreau misappropriated its “confidential, privileged, and proprietary property” (ECF No.
66 at 60 (capitalization omitted)). USOPC alleges several facts in support of this claim. For
instance, USOPC alleges that Dr. Moreau kept confidential information, including USOPC trade
secrets, without USOPC’s consent or knowledge (Id. at 62 ¶ 108). Furthermore, Dr. Moreau
“improperly shared” USOPC’s confidential and proprietary information with third parties (Id. at
59 ¶ 86). Accordingly, USOPC argues the Counterclaims “strictly involve” Dr. Moreau’s
“unlawful appropriation” of its confidential information, and therefore Dr. Moreau cannot meet
his step one burden under the anti-SLAPP statute (ECF No. 209 at 16).
This argument fails to persuade for several reasons. First, in the context of anti-SLAPP
motions, whether the documents are “privileged or confidential” is irrelevant at the first step of the
anti-SLAPP inquiry. See Fox Searchlight Pictures, Inc. v. Paladino, 89 Cal. App. 4th 294, 308
(2001). Second, that courts have held that the use of certain documents for pre-litigation purposes
is improper in other contexts does not mean that Dr. Moreau’s conduct falls outside the antiSLAPP statute’s ambit. Cf. Xyngular v. Schenkel, 890 F.3d 868, 874 (10th Cir. 2018) (concluding
district court did not abuse its discretion in sanctioning party where the “inquiry . . . was not
whether the [at-issue] documents were confidential” but whether the party “acted willfully [or] in
bad faith in a way” that abused the judicial process). In the anti-SLAPP context, a party’s use of
allegedly confidential information for pre-litigation purposes is only fatal at step one where the
use of that information is “conclusively demonstrated to have been illegal as a matter of law.”
Flatley v. Mauro, 39 Cal. 4th 299, 320 (2006) (emphasis added). See also Stevens, 2021 WL

17

1153059, at *3 (concluding party “survive[d] the first step” of anti-SLAPP inquiry where she did
“not dispute” that her activity was unlawful (quotation omitted)). Here, there are no allegations in
USOPC’s Counterclaims that conclusively establish Dr. Moreau’s alleged retention and disclosure
of USOPC’s confidential documents was illegal or “not in furtherance of the preparation” of his
lawsuit. See Fox, 89 Cal. App 4th at 308 (concluding party met anti-SLAPP’s step one burden
where the court could not say “from the record before [it]” that the party’s use of confidential
information was “not an act in furtherance of the preparation” of lawsuit). 14
Essentially, USOPC argues that Dr. Moreau cannot establish that its Counterclaims are
based on any petitioning activity protected under the anti-SLAPP statute (See ECF No. 209 at 13).
But USOPC cannot survive Dr. Moreau’s anti-SLAPP motion simply by “combining allegations”
of protected and nonprotected activity “under the label of one cause of action.” Fox, 89 Cal. App.
4th at 106 (quotation omitted); see also Peregrine Funding, Inc. v. Sheppard Mullin Richter &
Hampton LLP, 133 Cal. App. 4th 658, 674 (2005) (“question[ing]” the “exclusive focus” on issue
of alleged misconduct over allegations of “protected activity”). Reviewing the allegations in
USOPC’s Counterclaims, many concern Dr. Moreau’s use of USOPC’s confidential information
in connection with this lawsuit (See, e.g., ECF No. 66 at 59 ¶ 88). Despite the Counterclaims’ other
conclusory allegations that Dr. Moreau retained USOPC’s confidential information for personal
financial benefit, a careful reading of the Counterclaims shows that Dr. Moreau’s pre-litigation is
not “merely incidental” to USOPC’s claims (ECF No. 66 at 58 ¶ 82). See Haight Ashbury, 184
Cal. App. 4th at 1551.

14
In support of its argument that Dr. Moreau cannot meet his step one burden, USOPC points to allegations that Dr.
Moreau violated the terms of its “Confidentiality and No Prohibited Contact Statement” Agreement and USOPC’s
“Code of Conduct”—both of which required Dr. Moreau to “maintain the confidentiality” of its proprietary
information, and to return all confidential materials to USOPC “upon his termination” (Id. at 61, 62 ¶¶ 102-04, 106).
However, as discussed above, Fox forecloses this argument. See Fox, 89 Cal. App 4th at 308.

18

Allegations in USOPC’s Counterclaims demonstrate that Dr. Moreau’s use of its allegedly
confidential information was “an act” done in furtherance of protected activity under the antiSLAPP statute. Fox, 89 Cal. App. 4th at 106. USOPC’s counterclaim that Dr. Moreau
misappropriated its confidential information is based largely on Dr. Moreau’s protected activity.
See Peregrine Funding, Inc. v. Sheppard Mullin Richter & Hampton LLP, 133 Cal. App. 4th 658,
673 (2005) (“[T]he fact is that some of the alleged actions constituting these breaches of duty
involved petitioning activity . . . .” (original emphasis)). Colorado’s anti-SLAPP statute, like
California’s, covers claims “arising from any act of that person” protected by the statute. § 13-201101(3)(a) (emphasis added); cf. § 425.16(b)(1). See also Oasis West Realty, 51 Cal. 4th at 825
(“[The] task is solely to determine whether any portion of [the] causes of action have even minimal
merit within the meaning of the anti-SLAPP statute.”). For these reasons, the Court agrees with
Dr. Moreau that these allegations are sufficient to demonstrate that USOPC’s claim challenges
protected activity, and that he has met his step one burden under the anti-SLAPP statute (ECF No.
171 at 14-15). 15
2. Anti-SLAPP Step Two
Having concluded that Dr. Moreau has met his step one burden under the anti-SLAPP
statute, the Court now shifts to the second step of the anti-SLAPP inquiry. See L.S.S., 2022 COA
123, ¶ 22. USOPC brings counterclaims for conversion, civil theft, breach of contract, and
violations of the Defend Trade Secrets Act (“DTSA”) and Colorado Uniform Trade Secrets Act
(“CUTSA”) (ECF No. 209 at 16). USOPC contends essentially that it has a reasonable likelihood
Dr. Moreau also argues that USOPC’s Counterclaims should be dismissed because he has shown at step one of the
anti-SLAPP inquiry that he engaged in protected activity, and that USOPC cannot meet the “sham exception” under
Protect Our Mountain Environment, Inc. v. District Court, 677 P.2d 1361 (Colo. 1984) (See ECF No. 171 at 16-18;
see also ECF No. 215 at 7). The Court need not address Dr. Moreau’s arguments regarding POME’s application,
however, because Colorado’s anti-SLAPP law “codified and expanded the POME framework . . . .” L.S.S., 2022 COA
¶ 17. See also id. at ¶ 24 (adopting California’s two step anti-SLAPP inquiry as “consistent with the terms of
Colorado’s anti-SLAPP statute”).
15

19

of prevailing on its counterclaims because Dr. Moreau took confidential information in
contravention of various agreements with USOPC, did not return that information to USOPC, and
misappropriated its trade secrets (See ECF No. 209 at 17-18). Dr. Moreau does not explicitly
address the question of whether USOPC has met its step two burden under the anti-SLAPP statute.
Instead, he argues that his conduct did not rise to the level of conversion, civil theft, breach of
contract, or trade secret misappropriation (See ECF No. 215 at 9). The Court agrees with USOPC
that it has met its burden under step two of the anti-SLAPP statute.
In considering USOPC’s counterclaims, the Court construes Dr. Moreau’s argument as a
legal challenge to USOPC’s ability to meet its step two burden under the anti-SLAPP statute, and
applies the Rule 12(b)(6) standard in doing so. See Planned Parenthood, 890 F.3d at 834; see also
Todd, 2020 WL 60199, at *8 (“If the challenges are legal, the court evaluates those challenges
under a Rule 12 analysis.”); Tensor L. P.C. v. Rubin, No. 2:18-CV-01490-SVW-SK, 2019 WL
3249595, at *4 (C.D. Cal. Apr. 10, 2019) (“[T]he Court construes [the] anti-SLAPP motion as
challenging the legal sufficiency of [the] claims and will analyze [the] motion under the standards
set forth in Rule 12(b)(6).”). Under the Rule 12(b)(6) standard, USOPC’s burden under step two
of the anti-SLAPP inquiry is “minimal.” Tensor, 2019 WL 3249595, at *9.
USOPC has met this minimal burden for its conversion, civil theft, breach of contract, and
CUTSA claims. Accepting the Counterclaims’ allegations and true and interpreting the
Counterclaims in the light most favorable to USOPC, see Mayfield, 826 F.3d at 1255, USOPC has
alleged sufficient factual content to satisfy its burden at step two of the anti-SLAPP inquiry. For
example, regarding its conversion claim, USOPC has alleged that Dr. Moreau took USOPC’s
confidential and proprietary information without USOPC’s consent, and that, despite being asked
to do so, Dr. Moreau has not returned the confidential information he allegedly misappropriated

20

(See ECF No. 66 at 62 ¶¶ 108-111). See also Tan v. Det-CO, Inc., No. 17-CV-01678-NYW, 2018
WL 922133, at *15–16 (D. Colo. Feb. 15, 2018) (setting forth elements for conversion claims
under Colorado law). The Court need not address USOPC’s DTSA claim because an anti-SLAPP
motion “does not apply to claims asserted under federal law.” Iglesia Ni Cristo v. Cayabyab, No.
18-CV-00561-BLF, 2019 WL 3997474, at *2 (N.D. Cal. Aug. 23, 2019) (citing Hilton v. Hallmark
Cards, 599 F.3d 894, 901 (9th Cir. 2010)).
The Court harbors doubts that all of USOPC’s counterclaims will survive the factual
challenges brought by Dr. Moreau. At this time, the Court merely concludes that USOPC has met
its minimal burden under the anti-SLAPP statute’s second step. See Tensor, 2019 WL 3249595, at
*9; see also Nat’l Abortion Fed’n v. Ctr. for Med. Progress, No. 15-CV-03522-WHO, 2018 WL
5879786, at *4 (N.D. Cal. Nov. 7, 2018), aff’d, 793 F. App’x 482 (9th Cir. 2019) (stating that at
the “second step of the anti-SLAPP inquiry . . . required probability [of prevailing] need not be
high” (quotation omitted)).
***
In sum, with respect to Dr. Moreau’s legal challenges under the anti-SLAAP framework,
the Court has concluded that Dr. Moreau has met his first step burden under the anti-SLAPP statue.
USOPC has met its burden under step two of the anti-SLAPP inquiry as to its conversion, civil
theft, breach of contract, and CUTSA claims. Because the Court concludes that Colorado’s antiSLAPP statute does not apply to USOPC’s DTSA claim, the DTSA claim survives Dr. Moreau’s
motion for this procedural reason. See Iglesia Ni Cristo, 2019 WL 3997474, at *2.
D. Factual Challenge to USOPC’s Counterclaims
However, mindful that Dr. Moreau has also mounted factual challenges to USOPC’s
Counterclaims, the Court must assess those challenges after the parties have conducted discovery.

21

See, e.g., Planned Parenthood, 890 F.3d at 834. As explained above, discovery in this case is
closed and dispositive motions are imminently due. It would make little sense for this Court to
entertain factual challenges under the anti-SLAPP framework to USOPC’s Counterclaims when
the parties have now completed discovery but have not yet submitted those facts for this Court’s
consideration. 16 For this reason, this case is distinguishable from other cases concerning antiSLAPP motions, insofar as anti-SLAPP motions are typically adjudicated before or shortly after
discovery begins. See, e.g., Tensor, 2019 WL 3249595, at *3 (describing case’s procedural history
where the defendant filed an anti-SLAPP motion to strike the plaintiff’s second amended
complaint before discovery began).
Dispositive motions are due within two weeks. Therefore, to minimize the exhaustive
motion practice and briefing that has already occurred in this case, resolution of Dr. Moreau’s
factual challenges to USOPC’s Counterclaims under the anti-SLAPP framework will occur at the
summary judgment stage rather than on a motion to dismiss, as may be more typical under the
framework. Adjudicating Dr. Moreau’s factual challenges at summary judgment is entirely
consistent with the application of the anti-SLAPP statute in federal court. See Planned Parenthood,
890 F.3d at 834 (“[W]hen an anti-SLAPP motion to strike challenges the factual sufficiency of a
claim, then the Federal Rule of Civil Procedure 56 standard will apply.”). Moreover, adjudication
of Dr. Moreau’s factual challenges at summary judgment is in the best interests of the parties and
this Court. Discovery is complete and there is no point in bifurcating the factual reviews required
by the anti-SLAPP framework on the one hand, and Rule 56 on the other. As noted above, the
reviews are substantially similar. That would simply cause further delay in an extremely protracted
case.

16

Dr. Moreau’s Special Motion to Dismiss was filed on May 3, 2021, when little, if any, discovery had been conducted.

22

For the reasons set forth above, Dr. Moreau’s Special Motion to Dismiss USOPC’s
Counterclaims Pursuant to C.R.S. § 13-20-1101 (ECF No. 171, pubic entry 173) is denied.
III. ANALYSIS OF USOPC’S MOTION
Having considered Dr. Moreau’s First Amended Complaint, USOPC’s Motion, Dr.
Moreau’s Response, USOPC’s Reply, the parties’ subsequent supplemental briefing, and relevant
legal authority, the Court denies USOPC’s Motion to Dismiss (ECF No, 170). 17
The Court accepts as true the well-pleaded allegations in Dr. Moreau’s First Amended
Complaint and interprets those allegations in the light most favorable to him. See Mayfield, 826
F.3d at 1255. In the First Amended Complaint, Dr. Moreau alleges that, while employed at
USOPC, he discovered a sexual assault incident involving an athlete (See, e.g., ECF No. 103 at 89 ¶ 47). Dr. Moreau reported the incident to an upper-level manager at USOPC, who then
investigated the incident but declined to report the incident to law enforcement (See id. at 9 ¶ 49).
USOPC did not report the incident until Dr. Moreau e-mailed higher-level USOPC executives (Id.
at 9 ¶ 50).
Dr. Moreau discovered and reported similar incidents of misconduct that occurred at
USOPC facilities but alleges that USOPC failed to adequately address the severity of these
incidents (See, e.g., id. at 9-11 ¶¶ 54-60, 62). Dr. Moreau reported to United States Olympic
Committee lawyers that USOPC employees failed to meet the standards of care applicable to
maintaining athletes’ medical charts (See, e.g., id. at 11-12 ¶¶ 66, 69). Dr. Moreau also complained

After USOPC filed its dismissal motion, Dr. Moreau moved to amend the First Amended Complaint to seek
exemplary damages (See ECF No. 252). The Magistrate Judge subsequently issued an order granting Dr. Moreau’s
Motion to Amend (See ECF No. 270). In his amendment order, the Magistrate Judge specified that Dr. Moreau’s
“pleading changes” were limited to “those that concern the exemplary damages” (Id. at 6). USOPC then filed a
“renewed” Motion to Dismiss with supplemental authority (ECF No. 289). Dr. Moreau filed a Response to USOPC’s
renewed dismissal motion (ECF No. 292). The Magistrate Judge ruled that USOPC’s renewed dismissal motion and
Dr. Moreau’s Response should be construed as supplemental authority to USOPC’s originally filed Motion to Dismiss
(ECF No. 296).

17

23

to USOPC executives that USOPC failed to adequately address athletes’ mental health concerns
(See id. at 14-15 ¶¶ 78-88). Ultimately, Dr. Moreau’s repeated complaints about and opposition to
USOPC’s deficient practices culminated in his termination (See id. at 6-8 ¶¶ 29, 38, 43). In the
First Amended Complaint, Dr. Moreau asserts claims for wrongful discharge of public policy,
extreme and outrageous conduct, and abuse of process against USOPC, alleging that USOPC
terminated him based on his objections to USOPC’s deficient practices and that USOPC’s
Counterclaims are meritless (See ECF No. 103 at 37-41).
Reading the First Amended Complaint in its entirety, see Chilcoat v. San Juan County, 41
F.4th 1196, 1207 (10th Cir. 2022), Dr. Moreau has alleged plausible claims that meet the “low
bar” for surviving USOPC’s dismissal motion, Quintana v. Santa Fe Cnty. Bd. of Commissioners,
973 F.3d 1022, 1034 (10th Cir. 2020).
IV. CONCLUSION

Consistent with the above analysis, Dr. Moreau’s Special Motion to Dismiss Defendant
United States Olympic & Paralympic Committee’s Counterclaims Pursuant to C.R.S. § 13-201101 (ECF No. 171, public entry at 173) is DENIED, and USOPC’s Motion to Dismiss (ECF
No. 170) is DENIED.
DATED this 18th day of November 2022.
BY THE COURT:

___________________________________
Charlotte N. Sweeney
United States District Judge

24